博拓生物：关于首发结项募投项目节余募集资金永久补充流动资金的公告

Core Viewpoint - The company, Botao Bio, announced the approval of a proposal to permanently supplement its working capital with surplus funds raised from its initial public offering (IPO) during the second meeting of the fourth board of directors held on August 27, 2025 [1] Group 1 - The company will utilize a total of 166.463 million yuan (including accrued interest income and cash management income) from the surplus funds for working capital [1] - The actual amount to be used will be based on the balance of the special account on the day of the fund transfer [1]